Published in J Exp Med on January 01, 1976
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc Natl Acad Sci U S A (1988) 2.30
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Exclusive involvement of H-2Db or H-2Kd product in the interaction between T-killer lymphocytes and syngeneic H-2b or H-2d viral lymphomas. J Exp Med (1977) 1.64
Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A (1988) 1.60
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Genetic control of radiation leukemia virus-induced tumorigenesis. I. Role of the major murine histocompatibility complex, H-2. J Exp Med (1977) 1.54
Increased synthesis and expression of H-2 antigens on thymocytes as a result of radiation leukemia virus infection: a possible mechanism for H-2 linked control of virus-induced neoplasia. J Exp Med (1978) 1.53
Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. J Exp Med (1986) 1.50
Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol (1998) 1.39
Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad Sci U S A (1979) 1.38
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Persistence of infectious Friend virus in spleens of mice after spontaneous recovery from virus-induced erythroleukemia. J Virol (1979) 1.13
Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med (1988) 1.11
Role of natural killer cells in resistance against friend retrovirus-induced leukemia. J Virol (2001) 1.08
Differing T-cell requirements for recombinant retrovirus vaccines. J Virol (1996) 1.02
Genetic control of cell-mediated responsiveness to an AKR tumor-associated antigen: mapping of the locus involved to the I region of the H-2 complex. J Exp Med (1977) 1.01
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol (2010) 0.99
Immunological T-cell memory in the in vitro-induced experimental autoimmune orchitis: specificity of the reaction and tissue distribution of the autoantigens. J Exp Med (1978) 0.96
H-2D (Rfv-1) gene influence on recovery from Friend virus leukemia is mediated by nonleukemic cells of the spleen and bone marrow. J Exp Med (1980) 0.92
Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin Exp Immunol (1989) 0.90
Requirement for CD4(+) T cells in the Friend murine retrovirus neutralizing antibody response: evidence for functional T cells in genetic low-recovery mice. J Virol (1998) 0.84
Recovery from Friend disease in mice with reduced major histocompatibility complex class I expression. J Virol (1994) 0.84
Quantitative variations in the expression of H-2 antigens on murine leukemia virus-induced tumor cells can affect the H-2 restriction patterns of tumor-specific cytolytic T lymphocytes. J Exp Med (1981) 0.83
Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting. Bull World Health Organ (1987) 0.75
THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUES. J Exp Med (1964) 13.72
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology (1968) 11.20
Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol (1974) 11.12
Cytotoxic effects of lymphoid cells in vitro. Adv Immunol (1969) 8.18
Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J Natl Cancer Inst (1970) 6.08
Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci (1954) 5.72
A mouse B-cell alloantigen determined by gene(s) linked to the major histocompatibility complex. J Exp Med (1973) 5.55
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res (1960) 5.31
H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med (1975) 4.16
Quantitative in vitro assay of cytotoxic cellular immunity. J Natl Cancer Inst (1970) 3.12
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Passive transfer of transplantation immunity. Proc R Soc Lond B Biol Sci (1954) 2.84
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol (1974) 2.68
The effect of histocompatibility-2 type on response to friend leukemia virus in mice. J Exp Med (1968) 2.57
Studies of allograft immunity in mice. II. Mechanism of target cell inactivation in vitro by sensitized lymphocytes. Immunology (1970) 2.49
B-tropic Friend virus: a host-range pseudotype of spleen focus-forming virus (SFFV). Virology (1973) 2.34
Inheritance of susceptibility to Friend mouse leukemia virus. Jpn J Exp Med (1962) 2.10
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol (1975) 2.06
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Cell-mediated immunity to tumor cells. Adv Cancer Res (1974) 1.60
Properties of cell lines derived from tumors induced by Friend virus in BALB/c and BALB/c-H-2b mice. J Exp Med (1975) 1.55
Cellular immunity to herpes simplex virus mediated by interferon. J Exp Med (1974) 1.52
Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas. Int J Cancer (1972) 1.46
Thymus-derived lymphocytes produce an immunologically specific macrophage-arming factor. J Exp Med (1972) 1.43
Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst (1974) 1.38
Evidence for in vivo protection against murine-sarcoma virus-induced tumors by T lymphocytes from immune animals. J Immunol (1974) 1.27
Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice. J Immunol (1974) 1.09
Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma. Cancer Res (1973) 1.03
Nonspecific suppression of tumor growth by an immune reaction to Listeria monocytogenes. J Natl Cancer Inst (1974) 1.01
In vitro cytotoxicity studies of murine sarcoma virus-induced immunity in mice. J Natl Cancer Inst (1973) 1.00
Spontaneous regression in virus-induced murine leukemia. I. Host-virus system. J Natl Cancer Inst (1969) 0.92
Augmentation of the adoptive transfer of specific tumor immunity by non-specifically immunized macrophages. J Natl Cancer Inst (1973) 0.89
Immune response to Gross virus-induced lymphoma: comparison of two in vitro assays of cell-mediated immunity. J Natl Cancer Inst (1973) 0.86
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol (1990) 2.88
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. J Infect Dis (1991) 1.85
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol (1978) 1.66
The ultrastructure of normal and pathological IgM immunoglobulins. J Exp Med (1968) 1.64
Effect of murine host genotype on MCF virus expression, latency, and leukemia cell type of leukemias induced by Friend murine leukemia helper virus. Virology (1983) 1.62
Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res (1991) 1.61
Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
Purification and ultrastructure of Aleutian disease virus of mink. Nature (1975) 1.47
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol (1976) 1.41
Substitution of leucine for isoleucine in a sequence highly conserved among retroviral envelope surface glycoproteins attenuates the lytic effect of the Friend murine leukemia virus. Proc Natl Acad Sci U S A (1991) 1.40
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol (1989) 1.38
Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad Sci U S A (1979) 1.38
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36
Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem (1998) 1.35
Sequences in the U5-gag-pol region influence early and late pathogenic effects of Friend and Moloney murine leukemia viruses. J Virol (1990) 1.34
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines. J Gen Virol (1988) 1.28
Change in host cell tropism associated with in vitro replication of equine infectious anemia virus. J Virol (1989) 1.28
Pseudotyping of dual-tropic recombinant viruses generated by infection of mice with different ecotropic murine leukemia viruses. Virology (1985) 1.25
Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells. J Virol (1990) 1.24
The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. J Biol Chem (1974) 1.22
Leukemia induction by a new strain of Friend mink cell focus-inducing virus: synergistic effect of Friend ecotropic murine leukemia virus. J Virol (1984) 1.19
Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol (1995) 1.18
Characterization of a neurologic disease induced by a polytropic murine retrovirus: evidence for differential targeting of ecotropic and polytropic viruses in the brain. J Virol (1995) 1.18